Department of Laboratory Diagnostics, University Medical Centre Maribor, Maribor, Slovenia.
Department of Laboratory Medicine, Cliniques Universitaires St-Luc and Universite Catholique de Lovain, Brussels, Belgium.
Clin Chim Acta. 2020 Aug;507:75-87. doi: 10.1016/j.cca.2020.04.011. Epub 2020 Apr 16.
The Suppression of Tumorigenicity 2 protein (ST2) is a member of the interleukin (IL) 1 receptor family with transmembrane (ST2L) and soluble (sST2) isoforms that are (over)expressed in several cells in different conditions and following various triggers (e.g. inflammation, stress). The ligand of ST2 is IL-33, which on binding to ST2L results in nuclear signalling and immunomodulatory action in various cells (tumour, immune, heart). sST2, that is released in the circulation, functions as a »decoy« receptor of IL-33 and inhibits IL-33/ST2L signalling and beneficial effects. The importance and role of the ST2/IL-33 axis and sST2 have been evaluated and confirmed in several inflammatory, cancer and cardiac diseases. sST2 is involved in homeostasis/pathogenesis of these diseases, as the counterbalance/response on IL-33/ST2L axis activation, which is triggered and expressed during developing fibrosis, tissue damage/inflammation and remodelling. In clinical studies, sST2 has been recognised as an important prognostic marker in patients with cardiac disease, including patients with chronic kidney disease where specific characteristics of sST2 enable better assessment of the risk of End-Stage Renal Disease patients on dialysis. sST2 is also recognised as an important marker for monitoring treatment in heart failure patients. However, accurate measurement and interpretation of ST2 concentration in serum/plasma samples for routine and research applications require the use of appropriate methods and recognition of essential characteristics of both the methods and the analyte that may influence the result. sST2, as one of the most promising disease biomarkers, is deserving of further study and wider application in clinical practice.
抑制肿瘤发生 2 蛋白（ST2）是白细胞介素（IL）1 受体家族的成员，具有跨膜（ST2L）和可溶性（sST2）两种同工型，在不同条件下和多种触发因素（如炎症、应激）下，多种细胞中均有（过度）表达。ST2 的配体是 IL-33，与 ST2L 结合后，在各种细胞（肿瘤、免疫、心脏）中会产生核信号和免疫调节作用。在循环中释放的 sST2 作为 IL-33 的“诱饵”受体发挥作用，抑制 IL-33/ST2L 信号和有益作用。ST2/IL-33 轴和 sST2 的重要性和作用已在多种炎症、癌症和心脏疾病中得到评估和证实。sST2 参与这些疾病的稳态/发病机制，作为 IL-33/ST2L 轴激活的平衡/反应，该激活在纤维化、组织损伤/炎症和重塑的发展过程中被触发和表达。在临床研究中，sST2 已被确认为心脏病患者的重要预后标志物，包括慢性肾脏病患者，其中 sST2 的特定特征能够更好地评估透析终末期肾病患者的风险。sST2 也是心力衰竭患者监测治疗的重要标志物。然而，为了常规和研究应用，准确测量和解释血清/血浆样本中的 ST2 浓度需要使用适当的方法，并认识到可能影响结果的方法和分析物的基本特征。sST2 作为最有前途的疾病生物标志物之一，值得进一步研究和更广泛地应用于临床实践。
